Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

FOLFOXIRI tops doublets as bevacizumab backbone for mCRC

Key clinical point: Upfront treatment with fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab “significantly and meaningfully” improves overall survival in metastatic colorectal cancer when compared with chemotherapy doublets plus bevacizumab.

Major finding: There was a 4.4-month increase in median overall survival and an 11.6% increase in estimated 5-year overall survival with FOLFOXIRI plus bevacizumab.

Study details: An analysis of 1,697 patients pooled from five clinical trials.

Disclosures: There was no external funding for the analysis, but some of the original trials were sponsored by Roche. The lead author disclosed ties with Roche and other companies.


Cremolini C et al. J Clin Oncol. 2020 Aug 20. doi: 10.1200/JCO.20.01225.